Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasm Metastasis 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 14Paclitaxel 13Carboplatin 12Bevacizumab 7Specimen Handling 6Cisplatin 6olaparib 5Taxes 5Fulvestrant 5Nivolumab 4Megestrol Acetate 4Magnetic Resonance Spectroscopy 4Biopsy 4palbociclib 3durvalumab 3Oxaliplatin 3Leucovorin 3Letrozole 3Immunoglobulin G 3Fluorouracil 3Doxorubicin 3Docetaxel 3Disulfides 3trastuzumab deruxtecan 2ribociclib 2pertuzumab 2lenvatinib 2ipatasertib 2dostarlimab 2capivasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Alpelisib × 30 days × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡